A small molecule inhibitor of Rheb selectively targets mTORC1 signaling

Area of Science:

• Biochemistry
• Molecular Biology
• Cellular Signaling

Background:

• The mechanistic target of rapamycin complex 1 (mTORC1) is crucial for cell growth and metabolism.
• Dysregulated mTORC1 signaling is implicated in various diseases, including cancer, metabolic disorders, and fibrotic conditions.
• The small G-protein Rheb is a key activator of mTORC1 in response to growth factors.

Purpose of the Study:

• To discover and characterize a small molecule inhibitor targeting Rheb for selective mTORC1 blockade.
• To evaluate the specificity and efficacy of the novel inhibitor NR1 in vitro and in vivo.
• To explore the therapeutic potential of pharmacological Rheb inhibition.

Main Methods:

• Identification of a small molecule (NR1) binding to the Rheb switch II domain.
• Assessment of NR1's inhibitory effect on mTORC1-mediated phosphorylation of S6K1.
• Evaluation of NR1's selectivity against AKT and ERK phosphorylation.
• Comparison of NR1's effects with rapamycin, including mTORC2 inhibition.
• In vivo studies in mouse kidney and muscle to confirm NR1's efficacy.

Main Results:

• NR1 selectively binds Rheb's switch II domain, blocking mTORC1 activation.
• NR1 potently inhibits mTORC1-driven S6K1 phosphorylation without affecting AKT or ERK.
• Unlike rapamycin, NR1 does not inhibit mTORC2 upon prolonged exposure.
• NR1 demonstrates potent and selective mTORC1 inhibition in mouse kidney and muscle.

Conclusions:

• Pharmacological inhibition of Rheb is a viable strategy for selective mTORC1 targeting.
• NR1 represents a promising therapeutic agent for conditions associated with aberrant mTORC1 signaling.
• The selective inhibition profile of NR1 offers potential advantages over existing mTOR inhibitors.